Cibinqo(abrocitinib)
Cibinqo (abrocitinib) is a small molecule pharmaceutical. Abrocitinib was first approved as Cibinqo on 2021-12-09. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. It is known to target tyrosine-protein kinase JAK2 and tyrosine-protein kinase JAK1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cibinqo
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cibinqo | New Drug Application | 2024-01-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ABROCITINIB, CIBINQO, PFIZER | |||
| 2027-01-14 | NCE | ||
| 2026-02-09 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 2 | 2 | 8 | 2 | 12 | 26 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 2 | 2 | 8 | 2 | 12 | 26 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 3 | 8 | 2 | 9 | 22 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin diseases | D012871 | — | L00-L99 | — | 1 | 2 | — | 1 | 4 |
| Immune system diseases | D007154 | — | D89.9 | — | — | 2 | — | 1 | 3 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | 2 | — | — | 3 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | 2 | — | — | 2 |
| Genetic skin diseases | D012873 | — | — | — | — | 2 | — | — | 2 |
| Eczematous skin diseases | D017443 | — | — | — | — | 2 | — | — | 2 |
| Immediate hypersensitivity | D006969 | — | — | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | 1 | 2 |
| Pruritus | D011537 | HP_0000989 | L29 | — | 1 | — | — | — | 1 |
| Neurodermatitis | D009450 | — | L28.0 | — | 1 | — | — | — | 1 |
| Prurigo | D011536 | — | L28.2 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Granuloma | D006099 | — | — | — | 1 | — | — | — | 1 |
| Granuloma annulare | D016460 | — | L92.0 | — | 1 | — | — | — | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | — | — | — | — | 12 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | 1 | — | — | — | — | 1 |
| Stevens-johnson syndrome | D013262 | EFO_0004276 | L51.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 1 | 1 |
| Alopecia | D000505 | HP_0002293 | L64 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abrocitinib |
| INN | abrocitinib |
| Description | Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1 |
Identifiers
| PDB | — |
| CAS-ID | 1622902-68-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3655081 |
| ChEBI ID | — |
| PubChem CID | 78323835 |
| DrugBank | DB14973 |
| UNII ID | 73SM5SF3OR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cibinqo – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 779 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cibinqo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,352 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use